6:31 PM
 | 
Jun 02, 2008
 |  BC Extra  |  Top Story

Acorda gains on MS data

Acorda (NASDAQ:ACOR) gained $6.74 (31%) to $28.30 on Monday after reporting that Fampridine-SR met the primary endpoint in the Phase...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >